Skip to main content

Advertisement

SpringerLink
Log in

α1,2Fucosylation Is a Superior Predictor of Postoperative Prognosis for Colorectal Cancer Compared with Blood Group A, B, or Sialyl Lewis X Antigen Generated within Colorectal Tumor Tissues

  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

We have previously demonstrated tumor-specific α1,2fucosylation, which is associated with resistance of tumor cells to anticancer treatment in human colorectal tumor tissues. By using the YB-2 monoclonal antibody, the resulting products have been identified as Y, Leb, and H type 2 antigens in colorectal tumor tissues.

Methods

Immunohistochemical analyses of colorectal cancer tissues (74 specimens) were performed with a newly established mouse monoclonal antibody, YB-3 specifically recognizing H disaccharide (Fucα1,2Galβ) structures, and anti-A, anti-B, YB-2, and anti–sialyl Lewis X (SLX) antibodies, together with the analyses of glycosyltransferases involved in the synthesis of ABH antigens in the same tissues.

Results

The YB-3 antibody enabled us to detect colorectal tumors, particularly tumors in the distal large intestine and the rectum, with high sensitivity (74.3%) and specificity (100%). From immunohistochemical and enzymatic analyses of colorectal tissues, we found that once α1,2fucosylation had proceeded in tumor tissues, blood group A or B antigen was also synthesized in approximately half of the tissues of A or B blood type, but not in their normal tissues. A correlation of survival rate with immunostaining of tissues was found only by YB-3 antibody and not by anti-A, anti-B, or anti-SLX antibody.

Conclusions

As a predictor of postoperative prognosis of patients with colorectal cancer, immunodetection of α1,2fucosylated antigens with the YB-3 antibody seemed to be superior to blood groups A, B, or SLX antigen in colorectal tumor tissues.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

FIG. 1.
FIG. 2.
FIG. 3.
FIG. 4.
FIG. 5.

Similar content being viewed by others

References

  1. Hakomori S. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta 1999;1473:247–66

    PubMed  CAS  Google Scholar 

  2. Le Pendu J, Marionneau S, Cailleau-Thomas A, et al. ABH and Lewis histo-blood group antigens in cancer. APMIS 2001;109:9–31

    Article  PubMed  CAS  Google Scholar 

  3. Varki A. Glycosylation changes in cancers. In: Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth J, eds. Essentials of Glycobiology, Cold Spring Harbor NY: Cold Spring Harbor Press, 1999;537–49

    Google Scholar 

  4. Yazawa S, Nishihara S, Iwasaki H, et al. Genetic and enzymatic evidence for Lewis enzyme expression in Lewis-negative cancer patients. Cancer Res 1995;55:1473–8

    PubMed  CAS  Google Scholar 

  5. Nakamura J, Mogi A, Asao T, Nagamachi Y, Yazawa S. Evidence that the aberrant αl→2fucosyltransferase found in colorectal carcinoma may be encoded by Fuc-TIII (Le) gene. Anticancer Res 1997;17:4563–9

    PubMed  CAS  Google Scholar 

  6. Ørntoft TF, Greenwell P, Clausen H, Watkins WM. Regulation of the oncodevelopmental expression of type 1 chain ABH and Lewis(b) blood group antigens in human colon by alpha-2-L-fucosylation. Gut 1991;32:287–93

    PubMed  Google Scholar 

  7. Yazawa S, Akamatsu S, Tachikawa T, et al. Development and characterization of a novel anti-fucosylated antigen monoclonal antibody YB-2 and its usefulness in the immunohistochemical diagnosis of colorectal cancer. Jpn J Cancer Res 1993;84:641–8

    PubMed  CAS  Google Scholar 

  8. Akamatsu S, Yazawa S, Tachikawa T, et al. α2→3sialyltransferase associated with the synthesis of CA 19-9 in colorectal tumors. Cancer 1996;77:1694–700

    PubMed  CAS  Google Scholar 

  9. Naitoh H, Nakajima T, Nagamachi Y, Yazawa S. A clinicopathological evaluation of anti-fucosylated antigens antibody (YB-2) in colorectal carcinoma. Glycosylation Dis 1994;1:31–6

    Article  Google Scholar 

  10. Yazawa S, Nakamura J, Asao T, et al. Aberrant α1→2 fucosyltransferases found in human colorectal carcinoma involved in the accumulation of Leb and Y antigens in colorectal tumors. Jpn J Cancer Res 1993;84:989–95

    PubMed  CAS  Google Scholar 

  11. Yazawa S, Nishimura T, Ide M, et al. Tumor-related expression of α 1,2fucosylated antigens on colorectal carcinoma cells and its suppression by cell-mediated priming using sugar acceptors for α1,2fucosyltransferase. Glycobiology 2002;12:545–53

    Article  PubMed  CAS  Google Scholar 

  12. Sun J, Thurin J, Cooper HS, et al. Elevated expression of H type GDP-L-fucose: β-D-galactoside α-2-L-fucosyltransferase is associated with human colon adenocarcinoma progression. Proc Natl Acad Sci U S A 1995;92:5724–8

    Article  PubMed  CAS  Google Scholar 

  13. Orlow I, Lacombe L, Pellicer I, et al. Genotype and phenotypic characterization of the histoblood groups ABO(H) in primary bladder tumors. Int J Cancer 1998;75:819–24

    Article  PubMed  CAS  Google Scholar 

  14. Iwamoto S, Withers DA, Handa K, Hakomori S. Deletion of A-antigen in a human cancer cell line is associated with reduced promoter activity of CBF/NF-Y binding region, and possibly with enhanced DNA methylation of A transferase promoter. Glycoconjugate J 1999;16:659–66

    Article  CAS  Google Scholar 

  15. Kominato Y, Hata Y, Takizawa H, Tsuchiya T, Tsukada J, Yamamoto F. Expression of human histo-blood group ABO genes is dependent upon DNA methylation of the promoter region. J Biol Chem 1999;274:37240–50

    Article  PubMed  CAS  Google Scholar 

  16. Gao S, Worm J, Guldberd P, et al. Genetic and epigenetic alteration of the blood group ABO gene in oral squamous cell carcinoma. Int J Cancer 2004;109:230–7

    Article  PubMed  CAS  Google Scholar 

  17. Ichikawa D, Handa K, Withers DA, Hakomori S. Histo-blood group A/B versus H status of human carcinoma cells as correlated with haptotactic cell motility: approach with A and B gene transfection. Cancer Res 1997;57:3092–6

    PubMed  CAS  Google Scholar 

  18. Ichikawa D, Handa K, Hakomori S. Histo-blood group A/B antigen deletion/ reduction vs. continuous expression in human tumor cells as correlated with their malignancy. Int J Cancer 1998;76:284–9

    Article  PubMed  CAS  Google Scholar 

  19. Gao S, Bennett EP, Reibel J, et al. Histo-blood group ABO antigen in oral potentially malignant lesions and squamous cell carcinoma-genotypic and phenotypic characterization. APMIS 2004;112:11–20

    Article  PubMed  Google Scholar 

  20. Graziano SL, Tatum AH, Gonchoroff NJ, Newman NB, Kohman LJ. Blood group antigen A and flow cytometric analysis in resected early-stage non–small cell lung cancer. Clin Cancer Res 1997;3:87–93

    PubMed  CAS  Google Scholar 

  21. Yazawa S, Takeya A, Hosomi O, et al. Use of synthetic H disaccharides as acceptors for detecting activities of UDP-GalNAc:Fuc αl→2Gal β-R α1→3-N-acetylgalactosaminyltransferase in plasma samples from blood group A subgroups. Clin Chem 1992;38:2392–5

    PubMed  CAS  Google Scholar 

  22. Sobin LH, Wittekind C, eds. TNM: Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss, 2002

  23. Yazawa S, Madiyalakan R, Izawa H, et al. Cancer-associated elevation of α(l→3)-L-fucosyltransferase activity in human serum. Cancer 1988;62:516–520

    Article  PubMed  CAS  Google Scholar 

  24. Yazawa S, Asao T, Izawa H, et al. The presence of CA19-9 in serum and saliva from Lewis blood-group negative cancer patients. Jpn J Cancer Res 1988;79:538–43

    PubMed  CAS  Google Scholar 

  25. Akamatsu S, Yazawa S, Zenita K, et al. Elevation of an α(l,3)fucosyltransferase activity correlated with apoptosis in human colon adenocarcinoma cell line, HT-29. Glycoconj J 1996;13:985–93

    Article  Google Scholar 

  26. Nishihara S, Hiraga T, Ikehara Y, et al. Molecular mechanisms of expression of Lewis b antigen and other type 1 Lewis antigens in human colorectal cancer. Glycobiology 1999;9:607–16

    Article  PubMed  CAS  Google Scholar 

  27. Fujitani N, Liu Y, Toda S, et al. Expression of H type 1 antigen of ABO histo-blood group in normal colon and aberrant expressions of H type 2 and H type 3/4 antigens in colon cancer. Glycoconjugate J 2000;17:331–8

    Article  CAS  Google Scholar 

  28. Hakomori S. Tumor malignancy of defined by aberrant glycosylation and sphingo-(glyco)lipid metabolism. Cancer Res 1996;56:5309–18

    PubMed  CAS  Google Scholar 

  29. Lee JS, Ro JY, Sahin AA, et al. Expression of blood-group antigen-A—a favorable prognostic factor in non–small-cell lung cancer. N Engl J Med 1991;324:1084–90

    Article  PubMed  CAS  Google Scholar 

  30. Dabelsteen E. ABO blood group antigens in oral mucosa. What is new? J Oral Pathol Med 2002;31:65–70

    PubMed  CAS  Google Scholar 

  31. Marionneau S, Le Moullac-Vaidve B, Le Pendu J. Expression of histo-blood group A antigen increases resistance to apoptosis and facilitates escape from immune control of rat colon carcinoma cells. Glycobiology 2002;12:851–6

    Article  PubMed  CAS  Google Scholar 

  32. Nakagoe T, Nanashima A, Sawai T, et al. Expression of blood group antigens A, B and H in carcinoma tissue correlates with a poor prognosis for colorectal cancer patients. J Cancer Res Clin Oncol 2000;126:375–82

    Article  PubMed  CAS  Google Scholar 

  33. Nakagoe T, Fukushima K, Nanashima A, et al. Comparison of the expression of ABH/Lewis-related antigens in polypoid and non-polypoid growth types of colorectal carcinoma. J Gastroenterol Hepatol 2001;16:176–83

    Article  PubMed  CAS  Google Scholar 

  34. Sakuma Y, Kubishiro K, Tsukazaki K, Nozawa S. Involvement of H type 1 carbohydrate antigen in cell adhesion to vascular endothelial cells of human endometrial cancer. Anticancer Res 2003;23:1277–82

    PubMed  CAS  Google Scholar 

  35. Nakamura M, Kudo T, Narimatsu H, et al. Single glycosyltransferase, core 2 β1→6-N-actylglucosaminyltransferase, regulates cell surface sialyl-Lex expression level in human pre-B lymphocytic leukemia cell line KM3 treated with phorbolester. J Biol Chem 1998;273:26779–89

    Article  PubMed  CAS  Google Scholar 

  36. Mathieu S, Prorol M, Benoliel A, et al. Transgene expression of α(l,2)-fucosyltransfease-I (FUT1) in tumor cells selectively inhibits sialyl-Lewis x expression and binding to E-selectin without affecting synthesis of sialyl-Lewis or binding to P-selecin. Am J Pathol 2004;164:371–83

    PubMed  CAS  Google Scholar 

  37. Labarrière N, Pian JP, Otry C, et al. H blood group antigen carried by CD44V modulates tumorigenicity of rat colon carcinoma cells. Cancer Res 1994;54:6275–81

    PubMed  Google Scholar 

  38. Goupille C, Hallouin F, Meflah K, Le Pendu J. Increase of rat colon carcinoma cells tumorigenicity by α(l-2)fucosyltransferase gene transfection. Glycobiology 1997;7:221–9

    Article  PubMed  CAS  Google Scholar 

  39. Hallouin F, Goupille C, Bureau V, Meflah K, Le Pendu J. Increased tumorigenicity of rat colon carcinoma cells after 2-fucosyltranferase FTA anti-sense cDNA transfection. Int J Cancer 1999;80:601–11

    Article  Google Scholar 

  40. Cordel S, Goupille C, Hallouin F, et al. Role of α1,2fucosyltransferase and histo-blood group H antigen type 2 in resistance of rat colon carcinoma cells to 5-fluorouracil. Int J Cancer 2000;85:142–8

    Article  PubMed  CAS  Google Scholar 

  41. Goupille C, Marionneau S, Bureau V, et al. α1,2Fucosyltransferase increases resistance to apoptosis of rat colon carcinoma cells. Glycobiology 2000;10:375–82

    Article  PubMed  CAS  Google Scholar 

  42. Zerfaoui M, Fukuda M, Sbarra V, Lombardo D, El-Battari A. α(l,2)-Fucosylation prevents sialyl Lewis x expression and E-selectin–mediated adhesion of fucosyltransferase VII-transfected cells. Eur J Biochem 2000;267:53–60

    Article  PubMed  CAS  Google Scholar 

  43. Chihara Y, Sugano K, Kobayashi A, et al. Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene. Lab Invest 2005;85:895–907

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported in part by a Grant-in-Aid (No. 40212469) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Author information

Authors and Affiliations

  1. Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, 371-8511, Japan

    Kaori Tsuboi MD, Takayuki Asao MD, PhD, Munenori Ide MD, PhD, Shinji Hashimoto MD, Hiroyuki Kuwano MD, PhD & Shin Yazawa PhD

  2. Criminal Investigation Laboratory, Gunma Prefectural Police HQ, Maebashi, 371-0846, Japan

    Kasumi Noguchi PhD

  3. Department of Legal Medicine and Molecular Genetics, Graduate School of Medicine, Gunma University, Maebashi, 371-8511, Japan

    Yoshihiko Kominato MD, PhD

  4. Japan Immunoresearch Laboratories, Takasaki, 370-0021, Japan

    Abby R. Saniabadi PhD

  5. Tokushima Research Institute, Otsuka Pharmaceutical Co. Ltd., Tokushima, 771-0192, Japan

    Shin Yazawa PhD

  6. Innovation Center for Cooperative Research of Gunma University, Maebashi, 371-8511, Japan

    Shin Yazawa PhD

Authors
  1. Kaori Tsuboi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takayuki Asao MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Munenori Ide MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shinji Hashimoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kasumi Noguchi PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshihiko Kominato MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Abby R. Saniabadi PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroyuki Kuwano MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shin Yazawa PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shin Yazawa PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsuboi, K., Asao, T., Ide, M. et al. α1,2Fucosylation Is a Superior Predictor of Postoperative Prognosis for Colorectal Cancer Compared with Blood Group A, B, or Sialyl Lewis X Antigen Generated within Colorectal Tumor Tissues. Ann Surg Oncol 14, 1880–1889 (2007). https://doi.org/10.1245/s10434-007-9363-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-007-9363-2

Keywords

Search

Navigation